Mcintyre Freedman & Flynn Investment Advisers Inc Biogen Inc. Transaction History
Mcintyre Freedman & Flynn Investment Advisers Inc
- $138 Billion
- Q1 2024
A detailed history of Mcintyre Freedman & Flynn Investment Advisers Inc transactions in Biogen Inc. stock. As of the latest transaction made, Mcintyre Freedman & Flynn Investment Advisers Inc holds 1,089 shares of BIIB stock, worth $249,184. This represents 0.17% of its overall portfolio holdings.
Number of Shares
1,089
Previous 1,139
4.39%
Holding current value
$249,184
Previous $295 Million
20.33%
% of portfolio
0.17%
Previous 0.24%
Shares
4 transactions
Others Institutions Holding BIIB
# of Institutions
1,047Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.79 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.71 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.24 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.54 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.18 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $33B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...